Search Results - "Shu, Yamin"

Refine Results
  1. 1

    Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system by Shu, Yamin, Ding, Yiling, Liu, Lulu, Zhang, Qilin

    Published in CNS neuroscience & therapeutics (01-09-2023)
    “…Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to…”
    Get full text
    Journal Article
  2. 2

    A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib by Guo, Menglin, Shu, Yamin, Chen, Guosong, Li, Juan, Li, Feie

    Published in Scientific reports (29-11-2022)
    “…Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors…”
    Get full text
    Journal Article
  3. 3

    A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data by Zhang, Qilin, Ding, Yiling, Shu, Yamin, Chen, Jing

    Published in BMC cancer (11-08-2023)
    “…Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer…”
    Get full text
    Journal Article
  4. 4

    A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib by Yin, Yanchao, Shu, Yamin, Zhu, Junru, Li, Feie, Li, Juan

    Published in Scientific reports (15-11-2022)
    “…Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug…”
    Get full text
    Journal Article
  5. 5

    A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax by Yang, Yang, Shu, Yamin, Chen, Guosong, Yin, Yanchao, Li, Feie, Li, Juan

    Published in PloS one (07-12-2022)
    “…Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic…”
    Get full text
    Journal Article
  6. 6

    Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China by Zhang, Qilin, Wu, Pan, He, Xucheng, Ding, Yufeng, Shu, Yamin

    Published in Frontiers in oncology (01-12-2021)
    “…The purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in…”
    Get full text
    Journal Article
  7. 7

    Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system by Shu, Yamin, Chen, Jing, Ding, Yiling, Zhang, Qilin

    Published in Frontiers in immunology (15-05-2023)
    “…Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque…”
    Get full text
    Journal Article
  8. 8

    Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China by Shu, Yamin, Ding, Yufeng, Zhang, Qilin

    Published in Frontiers in oncology (20-04-2022)
    “…The purpose of this study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy vs. chemotherapy as first-line therapy in patients with…”
    Get full text
    Journal Article
  9. 9

    Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database by Shu, Yamin, Zhang, Qilin, He, Xucheng, Liu, Yanxin, Wu, Pan, Chen, Li

    Published in Frontiers in pharmacology (06-09-2022)
    “…Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin,…”
    Get full text
    Journal Article
  10. 10

    Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma by Liu, Lulu, Wang, Lei, Chen, Li, Ding, Yiling, Zhang, Qilin, Shu, Yamin

    Published in Frontiers in immunology (23-01-2023)
    “…Sintilimab plus chemotherapy significantly prolongs overall survival (OS) for patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC)…”
    Get full text
    Journal Article
  11. 11

    A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax by Yang Yang, Yamin Shu, Guosong Chen, Yanchao Yin, Feie Li, Juan Li

    Published in PloS one (07-12-2022)
    “…Background Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small…”
    Get full text
    Journal Article
  12. 12

    Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system by Shu, Yamin, He, Xucheng, Wu, Pan, Liu, Yanxin, Ding, Yufeng, Zhang, Qilin

    Published in Frontiers in public health (20-10-2022)
    “…Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world…”
    Get full text
    Journal Article
  13. 13

    Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database by Shu, Yamin, Ding, Yufeng, He, Xucheng, Liu, Yanxin, Wu, Pan, Zhang, Qilin

    Published in Cancer medicine (Malden, MA) (01-02-2023)
    “…Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also…”
    Get full text
    Journal Article
  14. 14

    Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis by Zhang, Wenting, Xu, Ziqi, Shu, Yamin, Shu, Sainan, Zhang, Qilin

    Published in Pharmaceuticals (Basel, Switzerland) (05-08-2024)
    “…Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for…”
    Get full text
    Journal Article
  15. 15

    Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system by Ding, Yiling, Su, Hongyan, Shu, Yamin, Chen, Jing

    Published in Heliyon (15-05-2024)
    “…Sotorasib has been approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Due…”
    Get full text
    Journal Article
  16. 16

    Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china by Shu, Yamin, Liu, Yanxin, He, Xucheng, Ding, Yufeng, Zhang, Qilin

    Published in Frontiers in pharmacology (12-08-2022)
    “…Objective: The aim of this study was to investigate the cost-effectiveness of olaparib as the maintenance therapy in patients with platinum-sensitive relapsed…”
    Get full text
    Journal Article
  17. 17

    Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system by Pan, Xianglin, Xiao, Xiangtian, Ding, Yiling, Shu, Yamin, Zhang, Wenting, Huang, Liu

    Published in Frontiers in pharmacology (09-07-2024)
    “…This study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS)…”
    Get full text
    Journal Article
  18. 18

    Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China by Shu, Yamin, Ding, Yufeng, He, Xucheng, Liu, Yanxin, Wu, Pan, Zhang, Qilin

    Published in Frontiers in pharmacology (20-09-2022)
    “…Objective: The purpose of this study was to estimate the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated advanced…”
    Get full text
    Journal Article
  19. 19

    Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System by Shu, Yamin, Ding, Yufeng, Liu, Yanxin, Wu, Pan, He, Xucheng, Zhang, Qilin

    Published in Frontiers in pharmacology (08-06-2022)
    “…Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab…”
    Get full text
    Journal Article
  20. 20

    A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan by Zhang, Yu, Zheng, Ziming, Yang, Xiawen, Pan, Xianglin, Yin, Lianglan, Huang, Xiao, Li, Qiang, Shu, Yamin, Zhang, Qilin, Wang, Kaiping

    Published in Food & function (20-06-2018)
    “…The aim of this study is to establish a rapid and sensitive method for detecting lentinan (LNT) in biosamples and to evaluate the pharmacokinetics of LNT in…”
    Get more information
    Journal Article